This 10 pharmaceutical companies, earned more than 150 billion in 2017!
January 29, 2018 As of January 25, 2018, a total of 130 pharmaceutical companies in the A share disclosed 2017 'report card', six for the performance of the newsletter, 124 for the performance notice, which Livzon Group, Jilin Ao East, letter Litas, Shanghai Laishi and other 10 net profit is expected to more than 1 billion yuan.
2017 annual net profit is expected to exceed 1 billion yuan medicine enterprise (Unit: ten thousand yuan)
Livzon Group: net profit ranked first
According to 2017 annual results notice, Livzon Group net profit of 4,220,717,700 -44,751,744 yuan, an increase of 451.04% -470.56% .For the substantial growth in performance, Livzon Group said that the company and its subsidiary Livzon Group Livzon Pharmaceutical Factory Transfer of subsidiary of Zhuhai Weixing Industrial Co., Ltd. 100% stake, the equity transfer was completed on July 17, 2017, is expected to increase this transaction will be attributable to shareholders of listed companies net profit of about 3.488 billion yuan. In addition, the company Business sales in all fields maintained a steady growth, which was also one of the reasons for the steady and steady growth of operating revenue and profits.
On December 23, 2017, Livzon Group issued a public announcement that it has obtained CFDA approved clinical approval for dantrolene sodium for injection, which was included in the prior review. On December 30, the announcement of the product approved clinical trial was released again. Approved is a recombinant human anti-RANKL monoclonal antibody injection.At the same time, in mid-December release announcement, the company and shareholders health RMB indirectly through indirect foreign SPV rose to Zhuhai monoclonal 306000000 yuan and 294000000 yuan (to maintain the same shareholding ratio), the move will help to speed up the research and development of monoclonal antibodies and the progress of the market.
According to statistics, including the above two products, a total of 6 new products have been clinically approved by Livzon Group in 2017. At present, the company already has 11 billion products and the new products will surely bring a positive stimulus to the Company's performance.
Wisdom fly creatures: amazing growth rate
In 2017, Zhifei Bio's performance was' a big turnaround 'with first-half net profit up 1326.96% YoY and full-year projected growth of 1191.5% ~ 1283.75% .China Life Sciences said that the industry policy changes triggered by the '18 vaccination industry event' in 2016 And other uncertainties are gradually eliminated, the industry has gradually implemented the new political and business environment has been further standardized and purify the company's own products and proxy Of the second category of vaccine products promotion and sales work continued to resume.In addition, the company fully carry out the production of vaccines, bidding, promotion, sales and so on.
Brokerage analysts pointed out that the Zhifei biological vaccine event, the performance of the most explosive company .The R & D strength is strong, follow-up a variety of innovations, multivalent vaccine will be more new products, to create a new profit growth.In addition, Exclusively listed 4-valent HPV vaccine marketed, will bring huge profits to the company.
Ji An Medical: Net profit from profit to tens of millions of pre-losing billion
According to the statistics, the net profit of Ji'an Medical in the first half of 2017 decreased by nearly 10% as compared to the same period of last year, and the estimated loss for the full year was 130 million to 150 million yuan with a change range of -1134.63% to -996.68%. The net profit in 2016 was 14,497,900 yuan Ann Medical said that it will continue to focus on 'wearable devices and smart hardware as the entrance into the field of mobile healthcare and health big data, and then around the user to establish a healthy ecosystem' strategy to build an integrated service innovation hardware and software service model, the previous raise investment The project will also continue to be gradually built.Transformation of the company to mobile medical has entered a crucial stage, need to continue to increase R & D investment.
It is understood that Ji'an Medical has made good progress in both B2B and B2C. At present, it has conducted in-depth cooperation with many professional medical institutions both at home and abroad on aspects of hardware and software, cloud platform, data analysis and treatment, etc., and served on chronic diseases patient.
List of FY 2017 Medical Expressions (Unit: 100 million yuan)
List of performance prediction of 2017 medical enterprises (Unit: ten thousand yuan)
